Sarepta Therapeutics, Inc. (SRPT): Price and Financial Metrics

Sarepta Therapeutics, Inc. (SRPT): $129.46

0.77 (-0.59%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SRPT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#65 of 363

in industry

SRPT Price/Volume Stats

Current price $129.46 52-week high $159.89
Prev. close $130.23 52-week low $55.25
Day low $127.83 Volume 786,422
Day high $131.16 Avg. volume 1,072,504
50-day MA $125.68 Dividend yield N/A
200-day MA $111.04 Market Cap 12.16B

SRPT Stock Price Chart Interactive Chart >

SRPT POWR Grades

  • Growth is the dimension where SRPT ranks best; there it ranks ahead of 93.58% of US stocks.
  • SRPT's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • SRPT ranks lowest in Stability; there it ranks in the 16th percentile.

SRPT Stock Summary

  • With a one year PEG ratio of 184.84, SAREPTA THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 83.94% of US stocks.
  • Of note is the ratio of SAREPTA THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 15.89% of US stocks have a lower such ratio.
  • SRPT's price/sales ratio is 7.93; that's higher than the P/S ratio of 86.54% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SAREPTA THERAPEUTICS INC are DCPH, CRIS, BCDA, CBAY, and RXRX.
  • Visit SRPT's SEC page to see the company's official filings. To visit the company's web site, go to www.sarepta.com.

SRPT Valuation Summary

  • In comparison to the median Healthcare stock, SRPT's price/sales ratio is 272.73% higher, now standing at 8.2.
  • Over the past 243 months, SRPT's price/earnings ratio has gone down 4.6.

Below are key valuation metrics over time for SRPT.

Stock Date P/S P/B P/E EV/EBIT
SRPT 2023-12-29 8.2 11.8 -13.1 -14.9
SRPT 2023-12-28 8.3 12.0 -13.2 -15.1
SRPT 2023-12-27 8.2 11.9 -13.1 -14.9
SRPT 2023-12-26 8.2 11.8 -13.0 -14.9
SRPT 2023-12-22 8.0 11.6 -12.8 -14.6
SRPT 2023-12-21 7.7 11.1 -12.3 -14.1

SRPT Growth Metrics

    Its 5 year revenue growth rate is now at 1772.43%.
  • Its year over year net cashflow from operations growth rate is now at 48.06%.
  • Its 5 year cash and equivalents growth rate is now at 540.35%.
Over the past 33 months, SRPT's revenue has gone up $495,214,000.

The table below shows SRPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 876.047 -262.28 -716.225
2022-06-30 835.184 -321.645 -506.631
2022-03-31 765.786 -363.976 -356.555
2021-12-31 701.887 -443.172 -418.78
2021-09-30 645.564 -588.381 -486.116
2021-06-30 600.082 -702.238 -634.471

SRPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRPT has a Quality Grade of C, ranking ahead of 59.75% of graded US stocks.
  • SRPT's asset turnover comes in at 0.231 -- ranking 185th of 682 Pharmaceutical Products stocks.
  • ORMP, AGIO, and JAZZ are the stocks whose asset turnover ratios are most correlated with SRPT.

The table below shows SRPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.231 0.864 -0.249
2021-06-30 0.213 0.868 -0.332
2021-03-31 0.201 0.872 -0.375
2020-12-31 0.186 0.883 -0.313
2020-09-30 0.190 0.886 -0.376
2020-06-30 0.192 0.879 -0.357

SRPT Price Target

For more insight on analysts targets of SRPT, see our SRPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $118.39 Average Broker Recommendation 1.5 (Moderate Buy)

Sarepta Therapeutics, Inc. (SRPT) Company Bio


Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.


SRPT Latest News Stream


Event/Time News Detail
Loading, please wait...

SRPT Latest Social Stream


Loading social stream, please wait...

View Full SRPT Social Stream

Latest SRPT News From Around the Web

Below are the latest news stories about SAREPTA THERAPEUTICS INC that investors may wish to consider to help them evaluate SRPT as an investment opportunity.

3 Things About Sarepta Therapeutics Every Smart Investor Knows

Mastering this stock requires appreciating a few scientific nuances.

Yahoo | December 28, 2023

15 Best Fast Growth Stocks to Buy Now

In this article, we will take a look at the 15 best fast growth stocks to buy now. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Best Fast Growth Stocks to Buy Now. Vanguard Growth ETF is one of the most famous growth focused […]

Yahoo | December 27, 2023

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […]

Yahoo | December 26, 2023

Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day

Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.

Yahoo | December 26, 2023

Sarepta Therapeutics Seen Expanding Duchenne Treatment Label

Sarepta Therapeutics may be on the cusp of expanding the label for its Duchenne Muscular Dystrophy treatment, according to Mizuho analyst Uy Ear. The company has submitted an efficacy supplement to the FDA for Elevidys, requesting expanded approval for all DMD patients. The treatment's current label restricts its use to 4- to 5-year-old ambulatory patients.

Yahoo | December 22, 2023

Read More 'SRPT' Stories Here

SRPT Price Returns

1-mo -8.53%
3-mo 34.25%
6-mo 6.80%
1-year -5.20%
3-year 79.18%
5-year 8.62%
YTD 34.25%
2023 -25.58%
2022 43.90%
2021 -47.18%
2020 32.12%
2019 18.24%

Continue Researching SRPT

Want to see what other sources are saying about Sarepta Therapeutics Inc's financials and stock price? Try the links below:

Sarepta Therapeutics Inc (SRPT) Stock Price | Nasdaq
Sarepta Therapeutics Inc (SRPT) Stock Quote, History and News - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!